Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Biosimilars
The date for the generics and biosimilars specialist Sandoz to spin out from its parent company Novartis has been announced. 25 September 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Pharmaceutical
French biopharma company Inventiva saw its US traded shares jump 11.1% to $4.19 yesterday, after it announced a deal with Japan-based Hepalys Pharma, a company incubated by Catalys Pacific. 22 September 2023
Biotechnology
UK-based Oxford Biomedica, a contract development and manufacturing organization (CDMO), is in talks to buy ABL Europe from family-owned French holding company Institut Mérieux in an all-share transaction. 21 September 2023
Pharmaceutical
Swiss pharma firm Acino has acquired M8 Pharmaceuticals, a specialty biopharmaceutical company focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil. 20 September 2023
Biotechnology
ALSA Ventures has announced the acquisition of Axovia Therapeutics Inc. 19 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Biotechnology
A new US biotech, Arialys Therapeutics, which is pioneering new therapeutics for autoimmune neuropsychiatry, has announced the closing of $58 million in seed financing. 15 September 2023
Biotechnology
AlveoGene, a UK-based company focused on transforming rare respiratory disease outcomes using inhaled gene therapy has announced its launch. 14 September 2023
Biotechnology
Dermatology and cosmetics company Pierre Fabre Laboratories has bought oncology specialist Vertical Bio, thus adding VERT-002 to its discovery pipeline. 12 September 2023
Biotechnology
Acquisitive US biotech Kriya Therapeutics yesterday revealed that it has acquired Tramontane Therapeutics, a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases. 7 September 2023
Pharmaceutical
A sizeable sum in excess of $7.75 billion was spent across pharmaceutical M&A in August. 4 September 2023
Biotechnology
Last week saw US biotech major Amgen reach a settlement with the Federal Trade Commission (FTC) regarding competition issues with its $27.8 billon proposed acquisition of Horizon Therapeutics, with particular issues concerning the potential bundling of the latter’s Krystexxa and Tepezza products. BridgeBio Pharma released new Phase III data on its acoramidis in ATTR cardiomyopathy at the European Society of Cardiology. On the deal-making front, ImmunoGen out-licensed its cancer treatment Elahere to Takeda for commercialization in Japan. The US Centers for Medicare and Medicaid (CMS) last Tuesday released the names of the first 10 drugs for price negotiations under the Inflation Reduction Act (IRA). Also of note, US biotech BioMarin Pharmaceuticals revealed it has treated a first patient with its gene therapy Roctavian for severe hemophilia A in Germany, marking the first commercial use in Europe. 3 September 2023
Biotechnology
The US Federal Trade Commission today announced it has reached a proposed consent order with Amgen to address what the agency saw as potential competitive harm that would result from the biotech major’s $27.8 billion acquisition of Horizon Therapeutics. 1 September 2023
Pharmaceutical
Japanese mid-size drugmaker Otsuka Pharmaceuticals has entered into a definitive arrangement agreement to acquire Toronto, Canada-based Mindset Pharma. 1 September 2023
Pharmaceutical
In a bid to consolidate its lead in the weight management therapy sector, diabetes care giant Novo Nordisk has now bought a fellow Denmark based company and its obesity program. 30 August 2023
Biotechnology
US health care tech conglomerate Danaher Corp said Monday it has agreed to acquire Abcam, just two months after the UK antibody research expert launched a strategic review of the company. 29 August 2023
Biotechnology
US biotech major Amgen last Monday announced that the US Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the supplementary new drug (sNDA) for full approval of its cancer drug Lumakras. US mRNA focused Moderna last week entered into a collaboration with China’s CARsgen Therapeutics to evaluate a CT041 combination as an mRNA cancer vaccine. US biotech start-up Cellares, which calls itself the first “integrated” development and manufacturing organization (IDMO), has secured $255 million in a series C financing. Also, Denmark’s Novo Nordisk last week presented new data extolling the benefits of its obesity management drug Wegovy (semaglutide) for patients with heart failure. 27 August 2023
Biotechnology
US trade body the Biotechnology Innovation Organization (BIO) said on Friday that it has filed an amicus brief opposing the Federal Trade Commission (FTC) lawsuit to block Amgen’s proposed acquisition of Horizon Therapeutics for $27.8 billion, arguing that the FTC’s overreach threatens the merger and acquisition activity that is the lifeblood of biotech innovation. 26 August 2023
Biosimilars
US pharmacy benefit manager (PBM) CVS Health today revealed it has set up a wholly-owned subsidiary, named Cordavis. 24 August 2023
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze